Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy
Bingtao Zhai,1 Yiying Zeng,2–5 Zhaowu Zeng,2–4 Nana Zhang,2–4 Chenxi Li,2–4 Yijun Zeng,2–4 Yu You,1 Shuling Wang,2–4 Xiabin Chen,2–4 Xinbing Sui,2–4 Tian Xie2–4 1College of Pharmacy, Chengdu University of Trad...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/dc9fed232122491faa7d219a65b3a7bf |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:dc9fed232122491faa7d219a65b3a7bf |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:dc9fed232122491faa7d219a65b3a7bf2021-12-02T04:02:54ZDrug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy1178-2013https://doaj.org/article/dc9fed232122491faa7d219a65b3a7bf2018-10-01T00:00:00Zhttps://www.dovepress.com/drug-delivery-systems-for-elemene-its-main-active-ingredient-beta-elem-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Bingtao Zhai,1 Yiying Zeng,2–5 Zhaowu Zeng,2–4 Nana Zhang,2–4 Chenxi Li,2–4 Yijun Zeng,2–4 Yu You,1 Shuling Wang,2–4 Xiabin Chen,2–4 Xinbing Sui,2–4 Tian Xie2–4 1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China; 2Holistic Integrative Pharmacy Institutes, Hangzhou Normal University, Hangzhou, Zhejiang, China; 3Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou, Zhejiang, China; 4Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou, Zhejiang, China; 5College of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China Abstract: β-elemene is a noncytotoxic Class II antitumor drug extracted from the traditional Chinese medicine Curcuma wenyujin Y. H. Chen et C. Ling. β-elemene exerts its effects by inhibiting cell proliferation, arresting the cell cycle, inducing cell apoptosis, exerting antiangiogenesis and antimetastasis effects, reversing multiple-drug resistance (MDR), and enhancing the immune system. Elemene injection and oral emulsion have been used to treat various tumors, including cancer of the lung, liver, brain, breast, ovary, gastric, prostate, and other tissues, for >20 years. The safety of both elemene injection and oral emulsion in the clinic has been discussed. Recently, the secondary development of β-elemene has attracted the attention of researchers and made great progress. On the one hand, studies have been carried out on liposome-based systems (including solid lipid nanoparticles [SLNs], nanostructured lipid carriers [NLCs], long-circulating liposomes, active targeting liposomes, and multidrug-loaded liposomes) and emulsion systems (including microemulsions, self-emulsion drug delivery systems [SEDDSs], and active targeting microemulsion) to solve the issues of poor solubility in water, low bioavailability, and severe phlebitis, as well as to improve antitumor efficacy. The pharmacokinetics of different drug delivery systems of β-elemene are also summarized. On the other hand, a number of highly active anticancer β-elemene derivatives have been obtained through modification of the structure of β-elemene. This review focuses on the two drug delivery systems and derivatives of β-elemene for cancer therapy. Keywords: β-elemene, pharmacokinetics, drug delivery system, derivative, safetyZhai BZeng YZeng ZZhang NLi CZeng YYou YWang SChen XSui XXie TDove Medical Pressarticleβ-elemenepharmacokineticsdrug delivery systemderivativesafetyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 6279-6296 (2018) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
β-elemene pharmacokinetics drug delivery system derivative safety Medicine (General) R5-920 |
| spellingShingle |
β-elemene pharmacokinetics drug delivery system derivative safety Medicine (General) R5-920 Zhai B Zeng Y Zeng Z Zhang N Li C Zeng Y You Y Wang S Chen X Sui X Xie T Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy |
| description |
Bingtao Zhai,1 Yiying Zeng,2–5 Zhaowu Zeng,2–4 Nana Zhang,2–4 Chenxi Li,2–4 Yijun Zeng,2–4 Yu You,1 Shuling Wang,2–4 Xiabin Chen,2–4 Xinbing Sui,2–4 Tian Xie2–4 1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China; 2Holistic Integrative Pharmacy Institutes, Hangzhou Normal University, Hangzhou, Zhejiang, China; 3Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, Hangzhou, Zhejiang, China; 4Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou, Zhejiang, China; 5College of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China Abstract: β-elemene is a noncytotoxic Class II antitumor drug extracted from the traditional Chinese medicine Curcuma wenyujin Y. H. Chen et C. Ling. β-elemene exerts its effects by inhibiting cell proliferation, arresting the cell cycle, inducing cell apoptosis, exerting antiangiogenesis and antimetastasis effects, reversing multiple-drug resistance (MDR), and enhancing the immune system. Elemene injection and oral emulsion have been used to treat various tumors, including cancer of the lung, liver, brain, breast, ovary, gastric, prostate, and other tissues, for >20 years. The safety of both elemene injection and oral emulsion in the clinic has been discussed. Recently, the secondary development of β-elemene has attracted the attention of researchers and made great progress. On the one hand, studies have been carried out on liposome-based systems (including solid lipid nanoparticles [SLNs], nanostructured lipid carriers [NLCs], long-circulating liposomes, active targeting liposomes, and multidrug-loaded liposomes) and emulsion systems (including microemulsions, self-emulsion drug delivery systems [SEDDSs], and active targeting microemulsion) to solve the issues of poor solubility in water, low bioavailability, and severe phlebitis, as well as to improve antitumor efficacy. The pharmacokinetics of different drug delivery systems of β-elemene are also summarized. On the other hand, a number of highly active anticancer β-elemene derivatives have been obtained through modification of the structure of β-elemene. This review focuses on the two drug delivery systems and derivatives of β-elemene for cancer therapy. Keywords: β-elemene, pharmacokinetics, drug delivery system, derivative, safety |
| format |
article |
| author |
Zhai B Zeng Y Zeng Z Zhang N Li C Zeng Y You Y Wang S Chen X Sui X Xie T |
| author_facet |
Zhai B Zeng Y Zeng Z Zhang N Li C Zeng Y You Y Wang S Chen X Sui X Xie T |
| author_sort |
Zhai B |
| title |
Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy |
| title_short |
Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy |
| title_full |
Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy |
| title_fullStr |
Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy |
| title_full_unstemmed |
Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy |
| title_sort |
drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy |
| publisher |
Dove Medical Press |
| publishDate |
2018 |
| url |
https://doaj.org/article/dc9fed232122491faa7d219a65b3a7bf |
| work_keys_str_mv |
AT zhaib drugdeliverysystemsforelemeneitsmainactiveingredientbetaelemeneanditsderivativesincancertherapy AT zengy drugdeliverysystemsforelemeneitsmainactiveingredientbetaelemeneanditsderivativesincancertherapy AT zengz drugdeliverysystemsforelemeneitsmainactiveingredientbetaelemeneanditsderivativesincancertherapy AT zhangn drugdeliverysystemsforelemeneitsmainactiveingredientbetaelemeneanditsderivativesincancertherapy AT lic drugdeliverysystemsforelemeneitsmainactiveingredientbetaelemeneanditsderivativesincancertherapy AT zengy drugdeliverysystemsforelemeneitsmainactiveingredientbetaelemeneanditsderivativesincancertherapy AT youy drugdeliverysystemsforelemeneitsmainactiveingredientbetaelemeneanditsderivativesincancertherapy AT wangs drugdeliverysystemsforelemeneitsmainactiveingredientbetaelemeneanditsderivativesincancertherapy AT chenx drugdeliverysystemsforelemeneitsmainactiveingredientbetaelemeneanditsderivativesincancertherapy AT suix drugdeliverysystemsforelemeneitsmainactiveingredientbetaelemeneanditsderivativesincancertherapy AT xiet drugdeliverysystemsforelemeneitsmainactiveingredientbetaelemeneanditsderivativesincancertherapy |
| _version_ |
1718401461820325888 |